Susan M. Domchek, MD

Abdou Y, Rozenblit M, Trapani D, Zerdes I, Boudreau E, Zhou Y, Adam V, Barrios C, Bousrih C, Branch V, Carey LA, Cameron D, Chen S, Chua BH, Davidson NE, Domchek SM, El-Abed S, El-Ashry D, Flowers M, Foldi J, Garber J, Goulioti T, Hodgdon C, Hung JL, Klar N, Norton L, Parajuli R, Piccart M, Pollastro T, Santa-Maria CA, Schumacher-Wulf E, Stecklein SR, Thulin A, Tovey H, Winer E, Wolff AC, Lin NU, O'Reilly S. Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2). NPJ 2026 May 11;12(1):69. Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2) , NPJ Breast Cancer, 11:12(1): 2026,69

Ongaro G, Salafia C, Sheikh R, Schofield E, Clark DF, Ebrahimzadeh J, Chittenden A, Stopfer JE, Brower J, Symecko H, Ovadia H, Husband A, Barr H, Mukherjee S, Hay JL, Stadler ZK, Offit K, Garber JE, Domchek SM, Robson ME, Hamilton JG. The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in Women with Pathogenic BRCA1/2 Variants , Genet Med: 2026

Hickey M, Tejada-Berges T, Domchek SM, Krejany EO, Brand A, Li P, Braat S, Kingsberg S. 2026 May;133(6):1188-1199. doi: 10.1111/1471-0528.70158. Epub 2026 Jan 22. Sexual Function, Activity and Distress 24 Months After Surgical Menopause: What Happens After Menopause (WHAM)-A Prospective Controlled Study. , BJOG, 133(6): 2026,1188-1199

Schopf C, Domchek SM, Tice JA, Eby PR, Mann R, Lehman CD, Cozzi A, Trivedi H, Lee JM. Risk Stratification for Breast Cancer Screening: AJR Expert Panel Narrative Review. Risk Stratification for Breast Cancer Screening: AJR Expert Panel Narrative Review. , AJR Am J Roentgenol.: 2026

Hu C, Sahu S, Chen W, Galloux M, Richardson ME, Bishop MF, Karam R, Pesaran T, Na J, Huang H, Weitzel JN, Nathanson KN, Yadav S, Boddicker NJ, Domchek SM, Monteiro AN, Iversen ES, Sharan SK, Couch FJ. Combining multiplexed assays of variant effect for enhanced BRCA2 variant classification. , Nat Commun.: 2026

Reiss KA, Xia M, Akamandisa M, D'Andrea K, Wubbenhorst B, Lord CJ, Pettitt SJ, Tutt ANJ, Brown TJ, O'Hara MH, Schneider C, Teitelbaum U, Hannan Z, Hood R, Tondon R, Vonderheide RH, Domchek SM, Nathanson KL. . Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial. , JAMA Oncol: 2026

Akamandisa MP, Xia M, Cheah W, Wubbenhorst B, D'Andrea KP, Fan M, Shilan JS, Pueschl D, Nayak A, McKenzie H, Tapper W, Copson ER, Cutress RI, Domchek SM, Eccles DM, Nathanson KL. Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer. , JCI Insight: 2026

Tung NM, Robson ME, Li T, Nanda R, Shah PD, Khoury K, Kimmick G, Santa-Maria C, Brufsky A, DeMeo M, Vieira JP, Carey LA, Wulf G, Domchek S, Krop IE, Wolff AC, Winer EP, Garber JE; Translational Breast Cancer Research Consortium (TBCRC). TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. , J Clin Oncol., 44(8): 2026,653-661

Godbole AR, Wood E, Egleston B, Hoffman-Andrews L, Brown S, Howe S, Shastri S, Mim R, Feng J, Owens A, Domchek S, Pyeritz R, Katona BW, Kallish S, Sirugo G, Weaver J, Fleisher L, Wen KY, Elkin E, Nathanson KL, Rader DJ, Bradbury AR. A randomized study of digital versus genetic counselor return of actionable genetic research results to biobank participants (RESPECT3 study). , BMC Med Ethics: 2026

Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X. Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment , Elife: 2026